Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class ASSE: 603168

Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase Ⅲ Clinical Trial of Litasert Eye Drops

· Issued by Zhejiang Shapuaisi Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Completion of Inclusion of the First Subject in Phase Ⅲ Clinical Trial of Litasert Eye Drops

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis